About Us
Pulmozyme Access Solutions: connecting patients to the medicine they need.
We are committed to helping all patients access our medicines, regardless of their ability to pay. Our dedicated staff of Specialists can help:
- Resolve benefits and coverage issues
- Find co-pay assistance for underinsured patients
- Provide free medicine for eligible uninsured patients through the Genentech® Access to Care Foundation (GATCF)
- Individualize services to meet your patients' specific needs
Since 1985, when its first product was approved, Genentech has donated approximately $1.5 billion in free medicine to uninsured patients through GATCF and other product donation programs. In addition, Genentech has donated approximately $250 million to various independent, non-profit organizations for co-pay assistance since 2005.
Pulmozyme® Access Solutions helps to resolve specific access and reimbursement issues for individual patients every day. Our dedicated Specialists help bring patient treatment and practice solutions together.
Pulmozyme (dornase alfa) Inhalation Solution Important Information
Indication and Usage
Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC 
40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.
Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF. When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.
For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF health care team.
Pulmozyme® is a registered trademark and the Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.
